Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CASP1 | P29466 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CASP7 | P55210 | 2/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689485 | 1.00 | PLAU (0.53) | PLAUALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL28989115 | 0.90 | PLAU (0.45) | PLAUALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL688709 | 0.85 | CTDSP1 (0.53) | PLAUALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL29061925 | 0.82 | CTDSP1 (0.41) | PLAUALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL9097608 | 0.81 | PLAU (0.53) | PLAUALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL11718995 | 0.81 | PLAU (0.53) | PLAUALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL5438141 | 0.79 | CYP1B1 (0.41) | PLAUALDH1A1HSD17B10CASP1HIF1A | |
| SCHEMBL689900 | 0.78 | ALDH1A1 (0.40) | PLAUALDH1A1HSD17B10CYP3A4CASP1 | |
| SCHEMBL30579742 | 0.78 | CYP1A1 (0.32) | PLAUCYP1A1CYP1B1 | |
| SCHEMBL9928987 | 0.77 | CYP1B1 (0.40) | ALDH1A1HSD17B10HIF1AKDM4ECYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101924-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2025-06-12 | — | — | US | disclosed |
| US-20250179093-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025059040-A1 | MUTANT KRAS MODULATORS AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-4397664-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-07-10 | — | — | EP | disclosed |
| CN-117222650-A | Pyridine or pyrimido-ring compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2022228568-A1 | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179093-A1 | KRAS MODULATORS | KRAS, NRAS, HRAS | PLAU 3466/4885ALDH1A1 4071/4885HSD17B10 3898/4885 |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | PLAU 3213/4885ALDH1A1 3593/4885HSD17B10 4743/4885 |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | PLAU 3213/4885ALDH1A1 3593/4885HSD17B10 4743/4885 |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | KRAS, NRAS, TP53 | PLAU 3711/4885ALDH1A1 3323/4885HSD17B10 3915/4885 |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | PLAU 3213/4885ALDH1A1 3593/4885HSD17B10 4743/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | PLAU 4517/4885ALDH1A1 1854/4885HSD17B10 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.